<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82882">
  <stage>Registered</stage>
  <submitdate>6/06/2008</submitdate>
  <approvaldate>24/07/2008</approvaldate>
  <actrnumber>ACTRN12608000355370</actrnumber>
  <trial_identification>
    <studytitle>Phase 1/2 study of immunotherapy of melanoma with dendritic cells pulsed with melanoma peptides or tumour extracts</studytitle>
    <scientifictitle>A phase 1/2 study to evaluate the effects of autologous dendritic cell (DC) vaccine (+ or - Interleukin-2) on respomse in patients with malignant melanoma.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Disseminated American Joint Committee on Cancer(AJCC ) Stage IV melanoma or locally recurrent melanoma.</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Metastatic Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1.Patients (pts) are stratifed by Tissue Typing &amp; then randomised into 2 groups, the two groups are Autologous Dendritric Cells (DC) alone or Autologous DC's plus Interleukin.  (IL-2) will be self-administered by sub cutaneous(sc) injection on inner thighs or lower abdomen at a dose of 1 million units/m2/day commencing 2 days after each DC injection and continuing for 5 days after the first 3 DC injections and 12 days after the 4th DC injections and 14 days after the final 3 vaccines.DC vaccine injections will be given at week 0,1,2,3,5,9,&amp; 13.All patients will  complete a follow up at week 14.  Patients will be equally allocated 2X2 to IL2. Patients will be required to have Computer Tomography (CT's) and Immunological blood examinations.DC are extracted from the patients blood.</interventions>
    <comparator>Autologous Dendtric Cells (DC's) plus Interleukin-2</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether DCs matured with a cytokine cocktail will be more effective at inducing immune and clinical responses to melanoma than DCs prepared without a maturation step.
This will be measeured by Computer Tomgraphy(CT) and Immunological blood examinations</outcome>
      <timepoint>Baseline and week 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate whether low dose IL-2 given after each Dendtric Cell vaccine will increase immune and clinical responses to melanoma.This will be measured by Computer Tomography (CT's) and Immunological blood examinations.</outcome>
      <timepoint>Baseline and week 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether clinical responses are more frequent in patients treated with Dendritic Cells plus peptides or Dendritic Cells plus autologous melanoma lysates, i.e. whether individual specific antigens may play a role in clinical responses.This will be measured by Computer Tomography (CT's) and Immunological blood examinations.</outcome>
      <timepoint>Baseline and week 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Patients of either sex with histologically confirmed melanoma.
2.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
3.Non-resectable, low volume metastatic melanoma that is measurable and which has failed chemotherapy or where chemotherapy has not been recommended.  Patients may be rendered low volume by partial surgical resection of their disease</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.No concomitant malignancy except for basal or squamous cell carcinoma of the skin or cone biopsied carcinoma of the cervix.
2.Chemotherapy or immunotherapy in the past four weeks or previous radiation therapy to target lesions.
3.Central Nervous System (CNS), spinal or bone metastases as the sole site of metastases.
4.Concomitant pregnancy.
5.Serum creatinine &gt;15mmol/L or raised bilirubin due to melanoma.
6.Concomitant infections or other serious medical illness.
7.Concomitant steroid or other immunosuppressive therapy.
8.Other serious illness requiring therapy unrelated to cancer.
9. Patients who are Human immunodeficiency virus (HIV) positive, Hepatitis B sag, Hepatitis C positive. (All formally screened)
10. Patients with cardiac or pulmonary impairment assessed from history and Eloectrocardigram (ECG).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>1.Patients (pts) are stratifed by Tissue Typing          2. Patients will be randomised by equal allocation.2 pts will be randomised to il2 then 2 pts without il2</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/02/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health &amp; Medical Research Council</primarysponsorname>
    <primarysponsoraddress>Mallett St
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>Mallett St
Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dendritic cells will be grown from metastatic melanoma patients' peripheral blood and used to present common tumour antigens (peptides) or tumour extracts as a vaccine. In addition, some patients will receive low dose IL-2 in addition to their vaccine. IL-2 has been shown to increase the life of cytotoxic lymphocytes generated in animal and human vaccines.</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service</ethicname>
      <ethicaddress>Royal Prince Alfred Hospital 
Missenden Rd 
Camperdown 2050</ethicaddress>
      <ethicapprovaldate>13/12/2002</ethicapprovaldate>
      <hrec>No X02-0308:</hrec>
      <ethicsubmitdate>1/11/2002</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Peter Hersey</name>
      <address>Cnr King &amp; Watt Sts
Newcastle NSW2300</address>
      <phone>0249 236 828</phone>
      <fax />
      <email>peter.hersey@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Lett</name>
      <address>Level 3 Gloucester House 
RPA 
Missenden Rd Camperdown NSW 2050</address>
      <phone>0299117304</phone>
      <fax>029954 9435</fax>
      <email>margaret.lett@smu.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Lett</name>
      <address>Level 3 Gloucester House 
RPA 
Missenden Rd Camperdown NSW 2050</address>
      <phone>0299117304</phone>
      <fax>99549435</fax>
      <email>margaret.lett@smu.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>